Site is Being Upgraded

Androsterone-based therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Dehydroepiandrosterone (DHEA) and its metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol)  increase PD-L1 expression,  augment Tregs function, promote immune tolerance, increase pancreatic β-cell proliferation and regeneration, increase insulin secretion, improve insulin sensitivity, increase energy utilization, and reverse TIDM, via up regulation of its target gene, 18/April/2018,  10.40 pm

Bonding your way to keep cardiac diseases at bay: Oxytocin-based intranasal inhalation therapy for cardiac rejuvenation: Oxytocin, a peptide hormone and neuropeptide known to play a role in empathy, generosity, child birth and so on, suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 18/April/2018, 10.17 pm
April 18, 2018
An essential oil-based therapy for Deafness: A therapeutic mix encompassing  Rosa mosqueta oil, Cholecalciferol, Ajoene and DIM (RMCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 18/April/2018, 11.25 pm
April 18, 2018
Show all

Introduction: What they say

A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan 20157, Italy; and Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA shows that “PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.” This research paper was published, in the 15 November 2017 issue of the journal “Science Translational Medicine” [One of the best research journals in Science with an I.F of 15 plus], by Prof. Fiorina P and Nasr MB and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Androsteronebased therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Dehydroepiandrosterone (DHEA) and its metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol)  increase PD-L1 expression,  augment Tregs function, promote immune tolerance, increase pancreatic β-cell proliferation and regeneration, increase insulin secretion, improve insulin sensitivity, increase energy utilization, and reverse TIDM, via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (2) Type 1 Diabetes (T1DM) constitutes about 5-10% (11 to 12 million) of all diabetic cases; (3) the incidence of T1DM is exponentially increasing year after year by 3%; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, while treatment for T1DM costs about $15 billion dollars per annum, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM;(ii) a side-effect-free natural product-based drug that does not harm or deplete adult stem cells; and (iii) a way to cure, not just treat, diabetes.


What is known?

Prof. Fiorina’s research team has recently shown that:(1) programmed death ligand 1 (PD-L1), the immune checkpoint regulator, is expressed poorly in hematopoietic stem and progenitor cells (HSPCs) of Type-1 diabetic (T1D) patients; (2) PD-L1 inhibits activated T-cells and thereby promotes immune tolerance; (3) the expression of PD-L1 is controlled by a network of miRNAs; (4) attenuating the expression of one of the miRNAs that target PD-L1 restores the expression of PD-L1 in HSPCs; (5) increasing the expression of PD-L1 in HSPCs, either genetically or pharmacologically, inhibits autoimmune response and reverses autoimmune diabetes; and (6) PD-L1 is expressed poorly in human HSPCs of T1D patients, suggesting that increasing the expression of PD-L1 in T1D patients may reverse and cure T1D.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, that an androsterone-based therapy for autoimmune diabetes. Dehydroepiandrosterone (DHEA) and its metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol), by increasing the expression of their target gene, they may increase the expression of PD-L1. Thereby, they may: (1) increase Regulatory T-cells(Tregs) function; (2) decrease immune activation; (3) increase pancreatic-β-cell proliferation and regeneration; (4) increase expression of genes that promote insulin sensitivity and insulin secretion;(4) decrease metabolic stress; and (5) promote glucose homeostasis (Fig.1). Thus,  pharmacological formulations encompassing dehydroepiandrosterone (DHEA)/ metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol), either alone or in combination with other drugs, may be used to treat autoimmune diabetes. Taken together, physicians/diabetologists may consider adopting dehydroepiandrosterone (DHEA) and its metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol)-based therapy in the treatment of autoimmune diabetes (T1DM).

Given the mechanism of action of taurineTaurine-based therapy may be used to  treat autoimmune diabetes (TiDM) (Fig.2).

Figure 1. Mechanistic insights into how dehydroepiandrosterone (DHEA) prevents the progression  of autoimmune diabetes (T1DM). Dehydroepiandrosterone (DHEA), by increasing the expression of its target genes, it may increase the expression of PD-L1. Thereby, it may prevent immune activation and attenuate the development of T1DM.

Figure 2. Dehydroepiandrosterone (DHEA)-based therapy may aid in the treatment of autoimmune diabetes through induction of PD-L1


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How do dehydroepiandrosterone (DHEA) and its metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol)  increase the expression of PD-L1?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Androsteronebased therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Dehydroepiandrosterone (DHEA) and its metabolite HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol)  increase PD-L1 expression,  augment Tregs function, promote immune tolerance, increase pancreatic β-cell proliferation and regeneration, increase insulin secretion, improve insulin sensitivity, increase energy utilization, and reverse TIDM, via up regulation of its target gene, 18/April/2018,  10.40 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

Comments are closed.